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BACKGROUND: Liver fibrosis evaluation is mandatory in non-alcoholic fatty liver
disease (NAFLD) and alcoholic liver disease (ALD) to decide the patient management.
Patients with these diseases are usually under the care of non-liver specialists who
refer them to specialized centers where the most accurate fibrosis tests are available.
We aimed to evaluate whether simple blood fibrosis tests available to all physicians
help to reduce the rate of unnecessary referral of NAFLD and ALD patients without
advanced fibrosis.
METHODS: NAFLD and/or ALD patients newly referred to our center for a non-
invasive evaluation of liver fibrosis were retrospectively included. The FibroMeter
(FM, combination of blood markers and Fibroscan results) was defined as the
reference test for specialized evaluation of liver fibrosis. A FM result <0.384 indicated
the absence of advanced fibrosis and thus an "unnecessary referral".
RESULTS: 558 patients were included (NAFLD: 283, ALD: 156, mixed NAFLD+ALD:
119). FM was <0.384 (unnecessary referral) in 58.8% of patients. FIB4 was <1.30 in
45.2% and eLIFT <8 in 47.7% of the patients. 84.9% of patients with FIB4 <1.30 and
85.3% of patients with eLIFT <8 had also FM <0.384. Therefore, using FIB4 or eLIFT
as first-line evaluation of liver fibrosis decreased by three-fold the rate of unnecessary
referral. The negative predictive value of FIB4 and eLIFT was >80% whatever the
underlying cause of chronic liver disease.
CONCLUSION: The use of eLIFT by non-liver specialists for NAFLD and ALD patients
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